Clinical Trial

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Protocol Amendment History 68 amendments
This ClinicalTrials.gov record has been amended 68 times since 2023-10-27; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2025-03-26
Status change: Not Yet Recruiting → Recruiting 2023-11-30
Trial Details
NCT Number NCT06113445
Lead Sponsor Incyte Corporation
Conditions NonSegmental Vitiligo
Enrollment 467 participants
Start Date 2023-11-29
Primary Completion 2026-02-24 (estimated)
Study Completion 2027-02-24 (estimated)
Updated on ClinicalTrials.gov 2026-03-23